HBOT Conversations:
Dr. Paul Harch & 8,101 Genes
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on 8,101 genes is the eighth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
In episode 8 of 9, host Edward di Girolamo speaks with world renowned HBOT expert, Dr. Paul G. Harch, about aging and the 8,101 genes HBOT affects.
di Girolamo starts this conversation with Dr. Harch bringing up the 8,101 genes that are activated by Hyperbaric Oxygen Therapy. The discussion leads to talk of Big Pharma, telomeres, reparative gene process, patents, and successful business models for HBOT clinics.
Dr. Harch explains that Hyperbaric Oxygen Therapy affects 8,101 of our genes, and it’s doing so on a different level for the ones that are overactive and abnormal in the disease process. He speaks of a 2004 lecture he gave to A4M about the effects of HBOT on longevity; and asks, “Where is senescence and aging based?”, answering with, “It’s in our DNA”. Dr. Harch dives in to how HBOT turns on our genes to grow new tissue and stimulates cellular repair and regeneration. di Girolamo agrees and brings up a different past lecture from Dr. Harch where Harch referred to Hyperbaric Oxygen Therapy as the ‘Fountain of Youth‘.
This series ends with Dr. Harch discussing a Buffalo VA study, and how the study subjects (comprised of older veterans) literally came alive and started propositioning nurses after Hyperbaric Oxygen Therapy treatments. He explained this is why no follow-up study was ever done because they weren’t expecting such and didn’t know what to do. Makes sense…. studies have shown success in HBOT treating erectile dysfunction.
If you are searching for the Fountain of Youth and ready to activate 8,101 genes in your body —- find a Hyperbaric Oxygen Therapy clinic near you.
Subscribe Now, It’s Free!
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Clinical Trial – Estimation of the Effective Dose (ED) 95 of Intrathecal Hyperbaric Prilocaine 2% for Scheduled Cesarean Delivery.
Prilocaine is a local anesthetic drug which as an intermediate duration of action shorter
than bupivacaine 0,5% that is usually used for spinal anesthesia in scheduled cesarean
section. No study has yet investigated the use of hyperbaric (HB) prilocaine 2% for
intrathecal anesthesia in cesarean section. The aim of this study is to determine the
Effective Dose (ED) 95 of hyperbaric (HB) prilocaine 2% by using the Continual Reassessment
Method (CRM)
Clinical Trial – Dosing of Carcinogenic Complexes After Anesthesia With Intrathecal Hyperbaric Prilocaine.
The prilocaine is a very common local anesthetic that has the disadvantage of being
metabolized to o-toluidine, a human carcinogen.
Hyperbaric 2% prilocaine (HP), recently developped, is increasingly used for spinal
anesthesia in ambulatory surgery. But the formation of carcinogenic metabolites induced by
the hyperbaric prilocaine is not yet known. The aim of this study is to investigate whether
the intrathecal administration of 50 mg hyperbaric prilocaine induces also the formation of
carcinogenic complexes such as urinary o-toluidine and hemoglobin adducts from o-toluidine in
blood.
Comparison of Two Different Treatment Protocols Using Systemic and Intratympanic Steroids with and without Hyperbaric Oxygen Therapy in Patients with Severe to Profound Idiopathic Sudden Sensorineural Hearing Loss: A Randomized Controlled Trial.
Abstract: This study aimed to investigate the efficacy of simultaneous steroid and hyperbaric oxygen therapy (HBOT) in patients with severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL), which has a poor prognosis. Sixty patients diagnosed with...